Delayed onset of castration resistance with serum T-based LHRH agonist regimens

A new paper just published online in Urology suggests that intermittent and testosterone (T)-based LHRH regimens are less likely to be associated with early onset of castration resistance than traditional, continuous, calender-based regimens. … READ MORE …

FDA formalizes warning of cardiovascular risks for LHRH agonists

According to a media release from the U.S. Food and Drug Administration (FDA) yesterday, the agency has asked manufacturers of the class of drugs known as luteinizing hormone-releasing hormone (LHRH) or gonadotropin-releasing hormone (GnRH) agonists to include warnings about risk for cardiovascular disease and diabetes in product labeling for these drugs. … READ MORE …

Are all LHRH agonists “just the same”?

When all the drugs in the same class have the same general clinical impact, this is known as a “class effect.” As an example, all statins (hydroxymethylglutaryl–coenzyme A reductase inhibitors) will lower risk for certain types of cardiovascular event because they lower levels of cholesterol. That is a “class effect.” … READ MORE …

US FDA reviewing the safety of LHRH agonists

For many years it has been understood by specialists that hormonal treatment of prostate cancer patients with luteinizing hormone releasing hormone (LHRH) agonists — also known as gonadatropin releasing hormone or GnRH agonists — is associated with metabolic side effects that include risks for cardiovascular disease and diabetes. … READ MORE …

The prostate cancer news report: Tuesday, May 5, 2009

We are returning to “normal” today with the standard “news reports.” Today’s items deal with:

  • Evolving biomarkers and new tests and their future application
  • MRI in diagnosis, staging, and prognosis of prostate cancer
  • Intraprostatic injection of LHRH agonists and antagonists: is it viable?
  • Gefitinib in HRPC: no evident impact on quality of life … READ MORE …

Efficacy and safety of the LHRH antagonist degarelix

Klotz et al. have now published the complete results of one of the Phase III clinical trials designed to evaluate the effectiveness and the safety of degarelix — a second-generation LHRH antagonist — in the management of hormone-sensitive prostate cancer. … READ MORE …